Envestnet Asset Management’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.18M Buy
55,753
+16,427
+42% +$1.06M ﹤0.01% 2595
2026
Q1
$2.22M Buy
39,326
+13,792
+54% +$898K ﹤0.01% 2943
2025
Q4
$2.05M Sell
25,534
-14,640
-36% -$984K ﹤0.01% 2805
2025
Q3
$1.96M Buy
40,174
+338
+0.8% +$20.9K ﹤0.01% 2891
2025
Q2
$2.97M Sell
39,836
-15,910
-29% -$1.05M ﹤0.01% 2537
2025
Q1
$3.54M Buy
55,746
+7,678
+16% +$522K ﹤0.01% 2366
2024
Q4
$3.75M Buy
48,068
+4,217
+10% +$339K ﹤0.01% 2300
2024
Q3
$3.52M Buy
43,851
+2,139
+5% +$173K ﹤0.01% 2326
2024
Q2
$3.45M Buy
41,712
+5,556
+15% +$489K ﹤0.01% 2274
2024
Q1
$3.09M Buy
36,156
+398
+1% +$31.2K ﹤0.01% 2304
2023
Q4
$3.06M Buy
35,758
+2,057
+6% +$178K ﹤0.01% 2207
2023
Q3
$3.02M Buy
33,701
+6,231
+23% +$556K ﹤0.01% 2129
2023
Q2
$2.34M Sell
27,470
-379,061
-93% -$32M ﹤0.01% 2180
2023
Q1
$2.09M Buy
406,531
+378,219
+1,336% +$30.6M ﹤0.01% 2174
2022
Q4
$2.23M Buy
28,312
+1,078
+4% +$86.6K ﹤0.01% 2087
2022
Q3
$2.02M Buy
27,234
+3,045
+13% +$219K ﹤0.01% 2091
2022
Q2
$1.58M Sell
24,189
-527
-2% -$31.2K ﹤0.01% 2255
2022
Q1
$1.56M Buy
24,716
+9,417
+62% +$512K ﹤0.01% 2358
2021
Q4
$811K Sell
15,299
-890
-5% -$54.2K ﹤0.01% 2762
2021
Q3
$1.14M Sell
16,189
-2,986
-16% -$188K ﹤0.01% 2449
2021
Q2
$1.28M Sell
19,175
-11,397
-37% -$806K ﹤0.01% 2361
2021
Q1
$3.39M Buy
30,572
+748
+3% +$92.6K ﹤0.01% 1636
2020
Q4
$3.54M Buy
29,824
+5,545
+23% +$597K ﹤0.01% 1442
2020
Q3
$2.12M Buy
24,279
+8,140
+50% +$711K ﹤0.01% 1592
2020
Q2
$1.45M Buy
16,139
+2,675
+20% +$270K ﹤0.01% 1763
2020
Q1
$1.34M Buy
13,464
+3,359
+33% +$364K ﹤0.01% 1644
2019
Q4
$1.16M Buy
10,105
+511
+5% +$61.8K ﹤0.01% 1927
2019
Q3
$1.21M Buy
9,594
+4,521
+89% +$574K ﹤0.01% 1828
2019
Q2
$610K Buy
5,073
+1,221
+32% +$120K ﹤0.01% 2268
2019
Q1
$337K Sell
3,852
-10,441
-73% -$950K ﹤0.01% 2547
2018
Q4
$1.43M Buy
+14,293
New +$1.5M ﹤0.01% 1525
2018
Q3
Sell
-18,049
Closed -$1.62M 1811
2018
Q2
$1.62M Sell
18,049
-7,906
-30% -$668K ﹤0.01% 880
2018
Q1
$1.9M Sell
25,955
-710
-3% -$48.7K 0.01% 727
2017
Q4
$1.55M Buy
26,665
+93
+0.3% +$4.9K ﹤0.01% 1043
2017
Q3
$1.19M Sell
26,572
-2,568
-9% -$107K ﹤0.01% 1097
2017
Q2
$1.15M Buy
29,140
+3,769
+15% +$155K ﹤0.01% 1120
2017
Q1
$1.03M Buy
25,371
+225
+0.9% +$8.79K ﹤0.01% 1212
2016
Q4
$1.01M Sell
25,146
-183
-0.7% -$6.9K ﹤0.01% 1180
2016
Q3
$917K Sell
25,329
-8
-0% -$275 ﹤0.01% 1293
2016
Q2
$735K Sell
25,337
-2,750
-10% -$83.1K ﹤0.01% 1475
2016
Q1
$982K Buy
28,087
+2,658
+10% +$85.8K ﹤0.01% 1317
2015
Q4
$820K Sell
25,429
-1,097
-4% -$35.6K ﹤0.01% 1376
2015
Q3
$857K Sell
26,526
-3,373
-11% -$127K ﹤0.01% 1357
2015
Q2
$1.24M Sell
29,899
-5,631
-16% -$237K 0.01% 1296
2015
Q1
$1.6M Buy
35,530
+34,937
+5,892% +$1.46M 0.01% 1086
2014
Q4
$22K Hold
593
﹤0.01% 1705
2014
Q3
$21K Buy
593
+63
+12% +$2.25K ﹤0.01% 1859
2014
Q2
$19K Buy
530
+221
+72% +$7.38K ﹤0.01% 1778
2014
Q1
$10K Sell
309
-341
-52% -$13K ﹤0.01% 1883
2013
Q4
$27K Buy
650
+263
+68% +$10.8K ﹤0.01% 1417
2013
Q3
$15K Sell
387
-96
-20% -$4.03K ﹤0.01% 1562
2013
Q2
$20K Buy
+483
New +$19.6K ﹤0.01% 1426

Other funds holding HAE

Envestnet Asset Management's HAE Position: Q2 2026 in Review

Envestnet Asset Management increased its Haemonetics (HAE) stake by 42% in Q2 2026, buying an estimated $1.06M and bringing the position to 55,753 shares worth $4.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2595.

Envestnet Asset Management first reported a position in HAE in Q2 2013 and has held it in 52 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Envestnet Asset Management held 55,753 shares of Haemonetics worth $4.18M as of Q2 2026.
  • Envestnet Asset Management bought 16,427 Haemonetics shares in Q2 2026, an estimated $1.06M.
  • Haemonetics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #2595 holding.
  • Envestnet Asset Management first reported a position in Haemonetics in Q2 2013 and has held it in 52 quarters since.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.